Katherine F Y Chan

Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study

C. Morash, I. Cagiannos, A. Zardan, 2022, BJUI compass.

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

S. Hotte, R. Hamilton, C. Wallis, 2022, Prostate Cancer and Prostatic Diseases.

Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.

C. Morash, I. Cagiannos, S. Hotte, 2022, Urologic oncology.

Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada

F. Saad, I. Cagiannos, S. Hotte, 2021, Cancers.

Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P).

A. Zardan, A. Feifer, V. Fradet, 2018 .

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.

J. Chin, A. Zardan, A. Feifer, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

CUAJ – Original Research Gotto et al PROs in mCRPCP: Final results of COSMiC

A. Zardan, A. Feifer, V. Fradet, 2020 .

Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer

I. Cagiannos, S. Hotte, R. Hamilton, 2021, JNCI Cancer Spectrum.

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

Simon E. Laganiere, Jamie L. Adams, L. Seeberger, 2023, The Lancet Neurology.